Foghorn Therapeutics Shifts Focus from Development Of Cancer Hopeful with Eye Cancer
Portfolio Pulse from Vandana Singh
Foghorn Therapeutics has announced data from a Phase 1 study of FHD-286 in metastatic uveal melanoma, validating its safety and tolerability. However, the company will not pursue FHD-286 for this condition. Instead, Foghorn plans to initiate a Phase 1 study of FHD-286 in combination with decitabine or cytarabine for relapsed and/or refractory AML patients. Earlier this month, the FDA lifted the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia and myelodysplastic syndrome.
June 28, 2023 | 3:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Foghorn Therapeutics is shifting its focus from uveal melanoma to AML, which could potentially impact the company's future revenues and stock price.
The company's decision to shift its focus from uveal melanoma to AML could potentially impact its future revenues and stock price. However, the impact is uncertain as it depends on the success of the new focus area.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100